ISSN 1662-4009 (online)

ESPE Yearbook of Paediatric Endocrinology (2018) 15 10.25 | DOI: 10.1530/ey.15.10.25

ESPEYB15 10 Type 1 Diabetes Mellitus Therapy and interventions (3 abstracts)

10.25 A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with T1DM in the home or school setting

Deeb LC , Dulude H , Guzman CB , Zhang S , Reiner BJ , Piché CA , Pradhan S & Zhang XM


Department of Pediatrics, Florida State University College of Medicine, Tallahassee, FL, USA


To read the full abstract: Pediatr Diabetes. 2018 19(5):1007-1013

Severe hypoglycemia is one of the most threatening events in management of diabetes for parents and relatives. Although parents and patients are taught about the management in the acute situation, many are unable to use injectable glucagon. For moderate hypoglycemia, injectable glucagon seems to be no alternative for most caregivers. Nasal glucagon is now available for clinical trials, but is not yet licensed for the market. The authors present a homecare setting trial that proves the concept of effectiveness and safety of nasal glucagon in children and adolescents. However, for market authorization there are still some steps to go, including with studies of pharmacodynamics in the situation of hypoglycemic blood glucose levels and randomized trials comparing injectable and nasal profiles. Nasal delivery would make management of moderate or severe hypoglycemia much easier. Also sick days management with low blood glucose levels could be more simple with low doses of nasal glucagon without hospitalization.